Novartis AG · SIX:NOVN
Novartis — Novartis FRESCO 2005 Analyst Meeting
15 slides from Novartis's conference presentation, Jan 19, 2006
Slide 1: Sandoz – Positioned for Growth
Sandoz – Positioned for Growth Andreas Rummelt CEO Sandoz Member of the Executive Committee of Novartis The following information contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “will” or “expec
Slide 2: Agenda; Generics Contribute to Long-Term Affordability of Health Care Systems
Agenda • Generics market environment • Sandoz performance 2005 • Strategic priorities and outlook 3 FRESCO 2005 / Andreas Rummelt / 2006-01-19 / Analyst Generics Contribute to Long-Term Affordability of Health Care Systems • Enable wider drug access • Allow significant savings for governments and pa
Slide 3: Future Industry Trends Favor Generics; Market Expected to Grow 11% Annually
Future Industry Trends Favor Generics, But Challenges Need to Be Watched Closely • Ongoing patent expiries of branded molecules Opportunities • Increasing generics penetration driven by regu- latory initiatives and cost containment measures • Emerging fast-growth markets (China, etc.) • Shift to hig
Slide 4: Generics Market Still Highly Fragmented with Two Key Players Leading
Generics Market Still Highly Fragmented with Two Key Players Leading the Global Market Total nine-month 2005 sales, in USD m Growth1 (%) Teva 3 849 11 Sandoz2 3 121 43 New Teva3 (incl. Ivax) Ivax 1 687 27 • Nine-month sales: Merck Gx 1 657 USD 5 536 m 14 •#1 Watson 1 218 3 Alpharma 1 095 18 Mylan 93
Slide 5: Top-line Growth Driven by Acquisition of Hexal / Eon Labs
Agenda • Generics market environment • Sandoz performance 2005 • Strategic priorities and outlook 9 FRESCO 2005 / Andreas Rummelt / 2006-01-19 / Analyst Top-line Growth Driven by Acquisition of Hexal / Eon Labs and Solid Organic Growth Third party net sales Dec 2005 YTD, in USD m Growth1 in % in USD
Slide 6: Strong Sales Growth in All Regions; Strong Bottom Line Growth
Strong Sales Growth in All Regions Third party sales per region, in % Retail sales driven by Latin Africa Australia & America (+21%1) Oceania (+82%1) • Hexal / Eon Labs (+11%1) acquisitions • Strong volume Asia 1 (+19%1) 4 3 expansion 7 • Successful launches • Authorized generics Europe • M&S invest
Slide 7: Difficult-to-make Generics as Key Differentiating Factor
Difficult-to-make Generics as Key Differentiating Factor vs. Generic Competitors Characteristics Example Sandoz Follow-on • Significant • Omnitrope biologics investments in (launched in Development / manufacturing difficulty technology and Australia) clinical studies Special • Advanced • MTX Hexal t
Slide 8: Authorized Generics from Novartis Pharma – Terbinafine (Lamisil) in Germany
Authorized Generics from Novartis Pharma – Example Terbinafine (Lamisil®) in Germany • Early entry launch of generic version of Novartis Pharma’s Lamisil® − Sandoz: May 2005, 3 months before patent expiry − Hexal: June 2005, 6 weeks before patent expiry • High market share1 for Novartis Group throug
Slide 9: Generics Key Success Factors; Four Strategic Priorities for Sandoz
Generics Key Success Factors – Strong Portfolio, Cost Competitiveness and Market Access • First to market Portfolio • Broad and global product portfolio − Difficult to make products − Wide range of galenical forms • Efficient and flexible supply chain Cost comp- etitiveness • Vertically integrated f
Slide 10: Integration Milestones Going Forward; Conclusion
Integration Milestones Going Forward 2006 2007 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Country Optimization of operations portfolios Technical Harmonization of supply chains operations Consolidation of production site network Product Short-term consolidation of Network Long-term development development center netwo
Slide 11: Sandoz Priorities and Expectations for 2006
Sandoz Priorities and Expectations1 for 2006 Priorities • Ensure delivery of planned launches on time • Maintain or expand market position in key markets • Achieve synergies from Hexal and Eon Labs integration Expectations • Retail growth with or even above market • Over-proportional bottom-line gro
Slide 12: Strong Presence Across the Globe; Centers of Excellence in Generics Development
Strong Presence Across the Globe Subsidiaries #1 in Rep office or trade alliance Europe #3 in Eastern Europe Entry into #2 in US China Entry into Strengthened Japan position in Brazil Strong position in India ) 23 FRESCO 2005 / Andreas Rummelt / 2006-01-19 / Analyst Centers of Excellence in Generics
Slide 13: Global Production Network; Sandoz Is Well Positioned for Future Growth
Global Production Network and Strong Technology Centers of Excellence Sandoz Germany: Hexal and Denmark: Oral solids, patches & implants, Eon Labs API pilot plant liquids, injectables, inhalers and Poland: APIs Canada: Oral solids Injectables Japan: US: Oral solids Oral solids China: Brazil: Oral so
Slide 14: Due to Strong Contribution of Hexal and Eon Labs; Q4 Sales Performance
... Due to Strong Contribution of Hexal and Eon Labs • Ranked #2 globally Leverage • More than twice the size of next largest player strong • Ranked #1 in Europe, #2 in the US market position • Hexal now ranked #1 in Germany • Elimination of development overlaps • Optimization of country portfolios
Slide 15: Q4 Operating Income Strongly Ahead of PY
Q4 Operating Income Strongly Ahead of PY Driven by Product Launches and Operational Efficiencies Operating income Q4 2005, in USD m Change % PY ACT (USD) Operating income excl. PPA 28 230 721 and integration costs • Sandoz 28 75 168 4 • Hexal / Eon Labs 155 • PPA and integration costs -111 – Amortiz